- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Preclinical Development of a UniStac®.based Long.acting Tetraspecific Drug for NASH | ||||||
| Recombinant Protein | NASH | FGF21,GLP.1,GCG,a.cytokine | Preclinical | Onegene Biotechnology Inc. | RS-2023-00282937 | ||
| 2 | LPA1 antagonist AMS-III-1086; Pre-clinical study for liver fibrosis treatment | ||||||
| Small Molecules | Liver fibrosis | LPAR1 | Preclinical | am SCIENCES | HN22C0594 | ||
| 3 | Pre-clinical study of YH34160 for obesity treatment | ||||||
| Recombinant Protein | Obesity | GDF15 | Preclinical | Yuhan | HN22C0555 | ||